Last reviewed · How we verify
Fenofibrate Combined With Ursodeoxycholic Acid
At a glance
| Generic name | Fenofibrate Combined With Ursodeoxycholic Acid |
|---|---|
| Also known as | UDCA 13-15mg/kg/d |
| Sponsor | Xijing Hospital of Digestive Diseases |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Fenofibrate in Primary Biliary Cholangitis: a Real World Study (PHASE3)
- Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis (PHASE3)
- Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis (PHASE2, PHASE3)
- Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study (PHASE3)
- Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis (PHASE2, PHASE3)
- Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis (PHASE3)
- Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid (PHASE3)
- Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |